J

James Larkin

Trinity College Dublin

ORCID: 0000-0001-5569-9523

Publishes on Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment. 1.4k papers and 132.5k citations.

PubIndex Score98Top 2%How it's scored

1.4kPublications

132.5kTotal Citations

First publication: 1966First senior author: 1968

Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers Renal cell carcinoma treatment Cutaneous Melanoma Detection and Management CAR-T cell therapy research

Top publicationsby citations

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Grant A. McArthur, Paolo A. Ascierto et al.|New England Journal of Medicine|2011

Cited by 7.7k

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin, Jedd D. Wolchok|New England Journal of Medicine|2019

Cited by 3.7k

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Antoni Ribas, Paolo A. Ascierto et al.|New England Journal of Medicine|2014

Cited by 2k

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

Georgina V. Long, John M. Kirkwood, Axel Hauschild et al.|New England Journal of Medicine|2017

Cited by 1.5k

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, James Larkin, Grant A. McArthur et al.|The Lancet Oncology|2016

Cited by 1k